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Abstract
Statins have been recommended for use in atherosclerotic cardio-cerebrovascular disease
(CCVD). The purpose of this study was to investigate the efficacy of five different types of
statin in the secondary prevention of CCVD in patients. This study retrospectively designed
and analyzed data from the National Health Insurance Service-National Health in Korea.
Participants aged 40 to 69 years were categorized into five statin groups (atorvastatin, rosu-
vastatin, pitavastatin, simvastatin, and pravastatin). The primary composite outcome was
defined as recurrence of CCVD or all causes of death. Cox proportional hazard regression
models were adopted after stepwise adjustments for confounders to investigate the differ-
ence in efficacy among the different statins. Of the 755 final participants, 48 patients experi-
enced primary composite outcomes. After adjustments, the hazard ratios (95% confidence
intervals) for primary composite outcomes of atorvastatin, pitavastatin, and rosuvastatin
groups were 0.956 (0.456–2.005), 1.347 (0.354–5.116), and 0.943 (0.317–2.803), respec-
tively, when compared with the simvastatin group. There were no significant differences
between the statins in efficacy for preventing recurrence of CCVD events and/or death in
CCVD patients.
Introduction
According to the World Health Organization fact sheet from 2017, atherosclerotic cardiovas-
cular disease (ASCVD) is the number one cause of death worldwide. In addition, approxi-
mately 17 million people died from ASCVD in 2016, accounting for 31% of all global deaths.
Of these deaths, 85% were reported to be due to a heart attack and/or stroke [1]. In Korea, the
socioeconomic burden of cardio-cerebrovascular disease (CCVD) is rapidly increasing.
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CCVD is the second leading cause of death in Korea and accounted for one-quarter of total
deaths in 2016 [2].
Strategies to prevent CCVD have important implications for substantially reducing mortal-
ity and related public health burdens. Dyslipidemia is the most important controllable risk
factor for atherosclerotic CCVD. According to several previously published cholesterol guide-
lines, statins are widely administered for primary and secondary prevention treatments of ath-
erosclerotic CCVD in individuals with dyslipidemia [3–6].
Various types of statins have been developed and approved for clinical use. Although most
statins share common mechanisms of action, their pharmacokinetics and dynamics differ, and
the clinical efficacy for improving patient lipid profiles and preventing ASCVD is unknown
among the different statins [7]. Additionally, in Korea, there is a lack of evidence on the effi-
cacy of each statin for the secondary prevention of CCVD compared with other statins.
The purpose of this study was to investigate the relationship between the use of five differ-
ent types of statins (atorvastatin, rosuvastatin, pitavastatin, simvastatin, and pravastatin) and
the composite outcomes (all causes of death and/or CCVD events) in CCVD patients using the
national cohort data.
Materials and methods
Data source and study population
Data from the Korean National Health Insurance Service–National Health Screening Cohort
(NHIS-HEALS) database, that was created based from the national health screening examina-
tions between 2002–2003, was used. The NHIS-HEALS cohort consists of 514794 persons and
represents approximately 10% of the 5.15 million eligible national health insurance subscribers
aged 40 to 79 years who have undergone national health screening examinations. All the study
participants received at least one health screening between January 2002 and December 2003.
The participants in the database received a follow-up health examination and submitted a life-
style and behavior survey, which included information on age, sex, socio-demographic factor,
medical record, and laboratory results. A detailed description of the study design and methods
was previously published [8].
The participants in this retrospective study were selected from the NHIS-HEALS cohort
(Fig 1). First, subjects were selected based on whether they had attended a health screening
since 2005 (n = 479,959). Next, participants were selected only if they satisfied all the following
conditions: (1) total cholesterol of�250 mg/dL, (2) been prescribed a statin since 2005, and
(3) diagnosed with CCVD between 2002 and 2004 (n = 5246). To maintain a homogeneous
participant pool, subjects were excluded according to the following criteria: (1) prescribed two
or more types of statins since 2005 (n = 2403), (2) prescribed a statin for�30 days since 2005
(n = 395), (3) prescribed statins which were not one of our target drugs since 2005 (n = 18),
and (4) participants with missing data in the confounding values criterion between 2005 and
2008 (n = 129).
To evaluate the differences among the different types of statins, the subjects were divided
into five groups: atorvastatin, pitavastatin, simvastatin, rosuvastatin, and pravastatin. Other
types of statins were not considered due to their small sample population. All participants took
only one type of statin in this study. Of a total of 5246 participants, 4491 subjects were
excluded. Finally, 755 individuals were included in this analysis (Fig 1).
This study was followed the guidelines of the Declaration of Helsinki (1975) and was
approved by the Chungbuk National University Hospital Institutional Review Board
(CBNUH-2019-07-013-001). Informed consent was waived as NHIS-HEALS were anon-
ymized at all stages including during data clearing and statistical analyses.
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Operational definition
In this study, we defined CCVD patients as having one or more of the primary diagnostic
codes, I20–I25 and I60–69, from the 10th edition of the International Classification of Disease
codes (ICD-10th codes). The primary composite outcome in this study was defined as the
recurrence of CCVD with ICD-10th codes I21-24, I63, I65, and I66 and/or all causes of death
since 2005. For further analysis, CCVD events were considered as secondary outcomes.
Study period
The start date of the study was the first diagnosis date of CCVD. For subjects who had recur-
rence or death, the end date was the first recurrence date of CCVD or the date of death since
2005, whichever occurred first. For the remaining subjects, the study end date was the last date
of the following events: (1) the most recent date of follow-up health screening, (2) the most
recent date of a hospital visit, or (3) the most recent date of statin administration.
Potential confounders
In this study, the following variables were considered as confounding variables: age, sex, body
mass index (BMI), systolic blood pressure (SBP), glucose, total cholesterol, alanine amino-
transferase (ALT) levels, a history of diabetes mellitus (DM), smoking status, alcohol
Fig 1. Flowchart of inclusion and exclusion criteria for participant selection method.
https://doi.org/10.1371/journal.pone.0247419.g001
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consumption, physical activity, and economic status. These confounding variables were
obtained from the records of the first health screening examinations. A history of DM, smok-
ing status, alcohol consumption, physical activity, and economic status were classified as cate-
gorical variables; the remaining confounding variables were classified as continuous. The
categorical variables, except for economic status, were extracted from self-reporting question-
naires and were recategorized for statistical analysis purposes: participants who answered
“Yes” to “Have you ever been diagnosed with diabetes?” were classified as “DM”; smoking sta-
tus was classified into two groups: “ever smokers” and “non-smokers”; alcohol consumption
was divided into three groups: “rare” (less than twice a month), “sometimes” (twice a month to
twice a week), and “often” (more than twice a week); physical activity was classified into three
groups: “rare” (individuals who did not exercise), “sometimes” (exercise between 1 and 4 days
per week), and “regular” (exercise more than 4 days per week); economic status was catego-
rized into three groups: “low” (�30th percentile), “middle” (>30th to�70th percentile), and
“high” (>70th percentile).
Statistical analysis
Continuous variables are expressed as mean ± standard deviation, while categorical variables
are expressed as a percentage of the cohort. To evaluate the differences among the different
types of statins, analysis of variance and Fisher’s exact tests were used. Kaplan-Meier methods
and log rank test estimates were used to compare the prevention of CCVD effects by individual
statin types. Cox proportional hazard (Cox-PH) models were performed to estimate the hazard
ratios (HRs) for primary composite outcomes. In this study, the Cox-PH models were per-
formed at three levels: model 1: age; model 2: age, smoking status, alcohol consumption, and
physical activity; and model 3: all variables in model 2 and included a history of DM, economic
status, BMI, SBP, ALT, and total cholesterol. All statistical tests were two-sided, and p-values
were defined as statistically significant if they were less than 0.05. The statistical package, SAS
Enterprise Guide version 7.1 (SAS Inc., Cary, NC, USA), and R (R Core Team, Vienna, Aus-
tria) were used to perform the analyses in this study.
Results
Of the 755 final participants in this study (485: atorvastatin, 34: pitavastatin, 8: pravastatin, 96:
rosuvastatin, and 132: simvastatin), 48 patients experienced the primary composite outcome
during the study duration and accounted for 6.36% of the study population. The median fol-
low-up duration was 12.4 years.
The baseline characteristics among five different statin groups are summarized in Table 1.
All variables considered for this study were not significantly different among the five different
statin groups. Although not statistically significant, individuals treated with simvastatin were
the oldest, while patients in the pravastatin group were the youngest (Table 1). Total choles-
terol levels were increased in pravastatin group and decreased in the rosuvastatin group. The
prevalence of DM was� 15% across all statin groups.
The findings of the Cox-PH models for the primary composite outcomes are presented in
Table 2. Compared with the simvastatin group, the HRs (95% confidence intervals [CIs]) for
the primary composite outcomes of the atorvastatin, pitavastatin, and rosuvastatin group were
0.875 (0.426–1.794), 1.238 (0.339–4.521), and 0.788 (0.267–2.323), respectively, after adjusting
for age (Cox-PH model 1). After fully adjusting for age, smoking status, alcohol consumption,
physical activity, BMI, SBP, total cholesterol, ALT, economic status, and DM, the HRs (95%
CIs) of the atorvastatin, pitavastatin, and rosuvastatin groups were 0.956 (0.456–2.005), 1.347
(0.354–5.116), and 0.943 (0.317–2.803), respectively (Cox-PH model 3). In the pravastatin
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Table 1. Baseline characteristics according to statin type.
Atorvastatin Pitavastatin Rosuvastatin Simvastatin Pravastatin p-value
Number of patients 485 34 96 132 8
Age, years 55.4 ± 6.6 55.0 ± 6.5 54.3 ± 6.2 56.5 ± 7.1 52.3 ± 6.9 0.081
BMI, kg/m2 24.8 ± 2.8 23.8 ± 2.6 24.0 ± 3.1 24.6 ± 2.9 24.6 ± 3.9 0.060
SBP, mmHg 126.4 ± 16.0 131.9 ± 17.0 124.8 ± 15.8 125.9 ± 15.8 126.3 ± 19.7 0.267
Glucose, mg/dL 96.5 ± 22.8 95.8 ± 15.5 96.2 ± 17.1 100.4 ± 31.0 94.4 ± 20.9 0.522
Total cholesterol, mg/dL 235.7 ± 50.1 240.1 ± 32.2 230.9 ± 32.4 240.7 ± 45.8 248.8 ± 27.7 0.504
ALT, IU/L 25.4 ± 14.8 22.5 ± 8.9 28.1 ± 26.6 28.5 ± 18.4 21.3 ± 13.2 0.151
DM, N (%) 99 (20.4) 10 (29.4) 15 (15.6) 39 (29.5) 2 (25.0) 0.066
Ever smokers, N (%) 101 (20.8) 7 (20.6) 25 (26.0) 33 (25.0) 1 (12.5) 0.669
Alcohol consumption, N (%) 0.759
Rare 324 (66.8) 26 (76.5) 71 (74.0) 92 (69.7) 7 (87.5)
Sometimes 125 (25.8) 7 (20.6) 18 (18.8) 28 (21.2) 1 (12.5)
Often 36 (7.4) 1 (2.9) 7 (7.3) 12 (9.1) 0 (0.0)
Physical activity, N (%) 0.741
Rare 229 (47.2) 18 (52.9) 49 (51.0) 66 (50.0) 3 (37.5)
Sometimes 195 (40.2) 13 (38.2) 36 (37.5) 44 (33.3) 3 (37.5)
Regular 61 (12.6) 3 (8.8) 11 (11.5) 22 (16.7) 2 (25.0)
Economic status, N (%) 0.541
Low 103 (21.2) 5 (14.7) 19 (19.8) 32 (24.2) 3 (37.5)
Middle 174 (35.9) 9 (26.5) 29 (30.2) 47 (35.6) 2 (25.0)
High 208 (42.9) 20 (58.8) 48 (50.0) 53 (40.2) 3 (37.5)
BMI: body mass index; SBP: systolic blood pressure; ALT: alanine aminotransferase; DM: diabetes mellitus.
https://doi.org/10.1371/journal.pone.0247419.t001
Table 2. Cox-proportional hazard regression models for primary composite outcomes for each statin compared
with simvastatin.
Model Statin HR (95% CI)












HR: hazard ratio; CI: confidence interval.
Model 1: adjusted for age.
Model 2: adjusted for sex and smoking status, alcohol consumption and physical activity in addition to the age
variable considered in Model 1.
Model 3: adjusted for body mass index, systolic blood pressure, total cholesterol, alanine aminotransferase, economic
status, and diabetes, in addition to the variables considered in Model 2.
https://doi.org/10.1371/journal.pone.0247419.t002
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group, the number of outcome events was insufficient; thus, there were no statistically realistic
results. The association between different statin types and the recurrence of CCVD events are
shown in Table 3. Compared with the simvastatin group, after fully adjusting for confounders,
the HRs (95% CIs) in the atorvastatin, pitavastatin, and rosuvastatin groups were 1.031 (0.479–
2.220), 1.412 (0.366–5.449), and 1.031 (0.340–3.123), respectively.
The survival analysis was performed using the Kaplan-Meier method and log rank test to
estimate the five statins’ effects on the primary composite outcomes and recurrence of CCVD
events as indicated in Fig 2. There were no statistically significant differences between the dif-
ferent types of statin (p-values > 0.05).
Discussion
The present study is a retrospective national cohort study that compared the efficacy of sec-
ondary prevention for CCVD among different types of statins using claim data from the NHIS
Table 3. Cox-proportional hazard regression models for the recurrence of cardio-cerebrovascular events for each
statin compared with simvastatin.
Outcome Statin HR (95% CI)




HR: hazard ratio; CI: confidence interval.
Adjusted for age, sex, smoking status, alcohol consumption, physical activity, body mass index, systolic blood
pressure, total cholesterol, alanine aminotransferase, economic status, and diabetes.
https://doi.org/10.1371/journal.pone.0247419.t003
Fig 2. Kaplan-Meier estimates of primary composite outcomes and cardio-cerebrovascular events. A) Primary composite outcomes of all causes of death and/or
recurrence of cardio-cerebrovascular disease (CCVD). B) Recurrence of cardio-cerebrovascular events.
https://doi.org/10.1371/journal.pone.0247419.g002
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in Korea. This study shows that there was no significant difference in preventing the recur-
rence of CCVD and/or death among five different types of statin in CCVD patients.
Statins were classified into three groups according to their reported LDL-cholesterol lower-
ing intensity. The intensity will depend on the individual dose, but in general, atorvastatin,
and rosuvastatin belong to moderate to high intensity groups, and the remaining statins are
classified as low or moderate intensity groups [9]. The 2018 American College of Cardiology/
American Heart Association guidelines recommend that patients with clinical atherosclerotic
CCVD should reduce their LDL-cholesterol with either a high-intensity statin therapy or via a
maximum tolerated statin therapy [10]. Due to their efficacy and safety, statins are widely
administered for primary and secondary prevention treatment of ASCVD in individuals with
dyslipidemia [3–6].
Different types of statins have different pharmacokinetics, as well as, varied clinical efficacies
to improve patient lipid profiles and to prevent ASCVD [7]. In particular, the degree of LDL-
cholesterol reduction achieved with statins appears different among Asian and Western
patients. Asian CCVD patients often have an increased response to statins. As a result, recom-
mended drug dosages often tend to be lower in Asian countries than in Western countries [11].
However, there is insufficient evidence to directly compare the efficacy of different statins in
the secondary prevention of CCVD events [12]. In addition, it is known that individual statins
have different efficacy on LDL-cholesterol reduction and HDL-cholesterol increase [13–15].
This study attempted to investigate whether there are differences in the secondary preven-
tive efficacy of different types of statins. To maintain a homogeneous participant pool, we
excluded subjects who were prescribed two or more statin types, or even one statin for�30
days. The results of this study show that there is no difference in the secondary prevention
effect between the different types of statins. These results show that classification according to
the intensity of LDL-cholesterol reduction for each statin may not have a significant difference
in the effect of secondary CCVD prevention. This is probably due to a more complex mecha-
nism besides the basic action of statins to reduce LDL-cholesterol [16, 17].
Statins inhibit HMG-CoA reductase activity in the mevalonate pathway. The mevalonate
pathway produces mevalonic acids, which are precursors of cholesterol and some non-sterol
isoprenoid derivatives. Isoprenoid derivatives play an important role in the regulation of vari-
ous cellular functions including proliferation, differentiation, and survival [18, 19]. Statins
inhibit the production of isoprenoid derivatives in the cholesterol pathway. Therefore, statins
are known to be pluripotent in their ability to modulate cell signalling and to reduce oxidative
stress and pro-inflammation [20]. In addition, since the data used in this study was obtained
in a real-world setting, it is necessary to interpret the results in consideration of the respective
conditions of the participants included in this study. For example, high-intensity statins may
be prescribed to participants who are at a higher risk of CCVD, while low-intensity statins
may be prescribed to participants with relatively low risk of CCVD. In addition, NHIS did not
provide a data regarding the participants’ detailed lifestyle and behaviors, such as dietary pat-
terns, which can affect the efficacy of secondary prevention, so these factors were not analyzed
in this study. There may be a confounding effect on secondary prevention between different
types of statin that was not accounted for in this study and future studies should consider die-
tary patterns in their analysis.
There are other limitations when interpreting the results of this study. First, several poten-
tially confounding factors have been adjusted, however some residual confounding effects
could not be completely controlled for in this study, and included lifestyle factors and/or
underlying genetic or familial conditions. We also could not include the non-statin lipid-low-
ering agents as confounders due to the limited availability of data. Second, the main lipid target
for the prevention of atherosclerotic CCVD is LDL cholesterol, but we were unable to include
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LDL cholesterol, triglycerides, and HDL cholesterol in our analysis. This is because the
NHIS-HEALS cohort data has been provided with detailed lipid profile since 2009, so there-
fore the baseline data could not be acquired. Instead of LDL cholesterol, we adopted total cho-
lesterol in our analysis. Third, since the operational definition of CCVD was determined based
on the ICD-10th codes, the participants in the study might not match actual CCVD patients in
a real-world scenario. In addition, major adverse cardiovascular events (MACE) may not coin-
cide precisely with the CCVD events that were operationally defined by the ICD-10th codes in
this study. Because the definition of MACE may vary from study to study [21], it may be diffi-
cult to accurately compare the result of this study with similar studies involving MACE. We
defined the recurrence of CCVD with ICD-10th codes I21-24, I63, I65, and I66 and/or all
causes of death. Fourth, to maintain a homogeneous participant pool, we excluded subjects
who were prescribed two or more statin types, or one statin for�30 days. Thus, the number of
participants in the statin group in this study was small. Similarly, due to the small number of
CCVD recurrences, it was not possible to analyze the effect of statins over time in detail. In
addition, the sample size of the “Pravastatin” group is small, which may affect the statistical
analysis. Therefore, we indicated “N/A” in the Tables 2 and 3. Large-scale clinical trials are
required to compare the secondary preventive effects of each statin type on CCVD. Fifth, we
could not guarantee that statin users took their medication as prescribed. Finally, selection
bias and confounding by indication may exists because many participants were excluded
based on inclusion and exclusion criteria.
Despite the several limitations, this study has several advantages. Of utmost importance, we
used the national cohort data that represents Korea’s total population based on true measure-
ments in clinical settings. In addition, since this study analyzed insurance claim data that
included disease diagnosis, health and lifestyle questionnaires, blood tests, such as lipid profil-
ing, and prescriptions, recall bias is minimized. Finally, regarding the effort to evaluate the dif-
ferences in efficacy between different types of statins, all participants in this study took only
one type of statin during a relatively long study period (median follow-up duration: 12.4
years). Thus, the long-term effect of secondary prevention was for each type of statin.
Conclusion
In conclusion, in this Korean study, no significant differences were observed in the efficacies
for preventing the recurrence of CCVD events and/or death according to different types of
statins administered to CCVD patients. However, further large-scale clinical trials regarding
the beneficial effects of secondary prevention of CCVD among individual statins are required.
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